Company

History

Aché Laboratórios Farmacêuticos S.A. is a company of 100% national capital. Aché has over the past 40 years consolidated its condition as a dynamic company by means of strategic domestic and foreign commercial partnerships, and the continuous development of products and services in order to meet the needs of health professionals and consumers, and the promotion of the well being and health of the population.

Its two industrial plants employ over 3,000 workers. The larger plant, located in the city of Guarulhos, Great São Paulo region, is also its administrative head-office. The second plant is located at Avenida Nações Unidas, in the south of the capital of São Paulo, and holds one of the biggest sales forces of the pharmaceutical industry in the country. Our annual balance sheet revealed a significant economic results, Ebitda ( Earnings Before Interests, Taxes, Depreciation, and Amortizations) included R$ 292 million.

Aché has a complete and diversified portfolio of prescription and over-the-counter drugs, in addition to a growing number of molecules of generic products manufactured under the Biosintética brand. Currently, over 250 brands are sold in about 600 presentations in the following classes: Anti-arthrosis, anti-infection, anti-inflammatory, cardiologic, dermatologic, endocrinologic, gastroenterological, oncologic, respiratory, women’s health, neurological drugs and vitamins.

National Leadership

Aché won the following certificates in 2001: ISO 14001 for environmental management, and OHSAS 18001 for occupational safety and health.

ASTA Medica was incorporated into Aché in 2003. The merger of the companies strengthened Aché’s position as the biggest pharmaceutical industry in Brazil.

Aché purchased the company Biosintética Farmacêutica in 2005. With the integration, Aché added over 250 treatment options.

Extensive Line of OTC and Generic Drugs

Over-the-counter (OTC) and generic drugs are one of the strong performance areas of Aché today. In addition to its leading brands such as Sorine®, Biofenac® Aerosol, Transpulmim®, Flagass® and Flogoral®, the company also invests in the extension of its OTC portfolio, with the migration of renowned prescription drugs such as the pain-killer and muscle relaxant Dorilax®, to beyond the drugstore and pharmacy counters throughout Brazil.

Focus on Innovation

Aché has always developed new drug presentations and versions, seeking the expansion of treatment options for doctors and patients. The company currently invests in the research and development of phytotherapeutic products developed from standardized plant extracts.
Acheflan® (Cordia verbenacea), launched in June 2005, was the first 100% national drug. It took seven years of studies and over R$ 15 million in research, partnerships with important national universities, and renowned, international researchers

Acheflan® (Cordia verbenacea) is an anti-inflammatory that comes in skin cream and aerosol versions, and is indicated in the treatment of chronic tendinitis and miofacial (muscle) pain. The oral version is already in study, in addition to research on its use in arthrosis of hand and knee, and dermatological. In addition to Acheflan, the company also has phytomedications developed from Brazilian plants.

Aché invests heavily in the development of synthetic drugs, especially in extra research, always in partnership with Brazilian research centers in order to promote national science.

Mission, Vision and Values

Vision

Be the best pharmaceutical lab in Brazil, preferred by consumers and health professionals, by making the access to innovative products and services possible, and which promote the health and well-being of the entire population.

Mission

Continuously make available with quality, creativity and convenience, innovative and accessible products and services that promote consumer health and well being, with motivated and qualified employees, and respect to people and the environment.

Values

Integrity
Respect to People
Respect to the Environment
Enterprising Spirit
Innovation
Sustainable Growth

Business Units

To use the most of the synergies of each area and offer products and services of the best quality, Aché is organized into Business Units, namely: Prescription Business Unit (I and II), OTC, Generics and Research, Development and Innovation (“PD&I”). These units are supported by the Commercial Center, Industrial Center, and the Corporate Center, which gather the following departments: Financial, Legal, Shared Services Center, HR, Medical-Scientific, and Risk Management. The company also has New Products department, which is dedicated to the renewal and growth of the Aché portfolio to meet the expectations of health professionals and consumer needs.